Incidence of Gastrointestinal Perforation in Users of ACTEMRA® (Tocilizumab), Rituxan® (Rituximab), Abatacept and Anti-Tumor Necrosis Factor Alpha Agents

23/12/2016
14/03/2024
EU PAS number:
EUPAS16960
Study
Finalised

ENCePP Code of conduct

No
Data sources

Data sources (types)

Administrative healthcare records (e.g., claims)
Drug dispensing/prescription data
Use of a Common Data Model (CDM)

CDM mapping

No
Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown
Data characterisation

Data characterisation conducted

No